Securities code: Lbx Pharmacy Chain Joint Stock Company(603883) securities abbreviation: Lbx Pharmacy Chain Joint Stock Company(603883) Announcement No.: 2022012 Lbx Pharmacy Chain Joint Stock Company(603883)
Announcement of resolutions of the 13th meeting of the 4th board of directors
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
● there is no objection or abstention in this board meeting.
● all the proposals of the board meeting were passed.
1、 Convening of board meeting
Lbx Pharmacy Chain Joint Stock Company(603883) (hereinafter referred to as “the company”) issued the notice of convening the 13th meeting of the 4th board of directors on March 3, 2022. The meeting was held on March 6, 2022 in the form of on-site and communication voting. 9 directors should participate in the voting and 9 directors actually participated in the voting. The meeting has gone through appropriate notification procedures, the meeting procedures comply with relevant laws and regulations and the articles of association, and the meeting and resolutions adopted are legal and effective.
2、 Deliberations of the board meeting
The meeting considered and adopted the following proposals:
(I) the proposal on changing the implementation location of some raised investment projects was deliberated and adopted
The company agrees to change the implementation location of the raised investment project ” Huadong Medicine Co.Ltd(000963) product sorting and processing project”. The independent directors of the company have expressed their independent opinions on this matter.
See the website of Shanghai Stock Exchange on the same day for details（ http://www.sse.com.cn. ）Announcement of Lbx Pharmacy Chain Joint Stock Company(603883) on changing the implementation location of some raised investment projects (Announcement No.: 2022014).
Voting results: 9 in favor, 0 against and 0 abstention, passed by vote.
(II) the proposal on terminating the acquisition of 51% equity of Hebei Huatuo pharmacy pharmaceutical chain Co., Ltd. was deliberated and adopted
See the website of Shanghai Stock Exchange on the same day for details（ http://www.sse.com.cn. ）Announcement of Lbx Pharmacy Chain Joint Stock Company(603883) on terminating the acquisition of 51% equity of Hebei Huatuo pharmacy pharmaceutical chain Co., Ltd. (Announcement No.: 2022015).
Voting results: 9 in favor, 0 against and 0 abstention, passed by vote.
(III) the proposal on acquiring 719643% equity of Hunan Huairen Health Industry Development Co., Ltd. was deliberated and adopted
The company is approved to acquire 719643% equity of Hunan Huairen Great Health Industry Development Co., Ltd. The independent directors of the company expressed independent opinions on the independence of the evaluation institution of this transaction, the rationality of the evaluation assumptions, the correlation between the evaluation method and the evaluation purpose, and the fairness of the evaluation pricing.
See the website of Shanghai Stock Exchange on the same day for details（ http://www.sse.com.cn. ）Announcement of Lbx Pharmacy Chain Joint Stock Company(603883) on the acquisition of 719643% equity of Hunan Huairen Great Health Industry Development Co., Ltd. (Announcement No.: 2022016).
Voting results: 9 in favor, 0 against and 0 abstention, passed by vote.
This proposal needs to be submitted to the general meeting of shareholders for deliberation and approval.
(IV) the proposal on convening the second extraordinary general meeting of shareholders in 2022 was reviewed and approved, and the company agreed to hold the second extraordinary general meeting of shareholders in 2022 on March 22, 2022 and review relevant proposals.
Voting results: 9 in favor, 0 against and 0 abstention, passed by vote.
It is hereby announced
Lbx Pharmacy Chain Joint Stock Company(603883) board of directors March 6, 2022
